In a July 25, 2025 article, Pain News Network highlights CureLab Oncology’s pioneering work with Elenagen, a DNA‑based therapy originally developed for cancer. In a pilot study involving 17 dogs suffering from severe osteoarthritis, weekly intramuscular injections of Elenagen led to meaningful improvements—90% of the dogs experienced at least a one‑point reduction in Pain Severity Score and a two‑point drop in Pain Interference Score. Limiting limping and boosting mobility and playfulness were observed, all without any treatment-related adverse effects. Dr. Alexander Shneider, CEO of CureLab Oncology, commented that the therapy may “help the body to manufacture its own multi‑modal anti‑inflammatory—without opioids or steroids.”

This feature in Pain News Network, a respected source focusing on pain research and relief strategies, underscores the translational potential of CureLab Oncology’s Elenagen. The article spotlights how a cancer-originated DNA therapeutic may offer a safe, non-opioid, disease-modifying alternative for chronic pain management—not just in pets, but potentially in humans. Pain News Network’s coverage brings important attention to Elenagen’s novel mechanism and aligns CureLab Oncology with emerging, interdisciplinary solutions to combat chronic inflammation and pain.

Read the article here, and the original press release here.